1 ties of this system for quantitative feature
subanalysis.
2 n in all patients who underwent lesion-based
subanalysis.
3 ine endocrine therapy, were included in this
subanalysis.
4 tcomes among each variable underwent further
subanalysis.
5 nt cohorts and incident type 2 diabetes in a
subanalysis.
6 milar findings were observed in the low-bias
subanalysis.
7 x differences were studied as a prespecified
subanalysis.
8 hose <15 years of age were excluded from the
subanalysis.
9 igibility criteria and were included in this
subanalysis.
10 confidence interval: 1.01-4.46) for NODAT in
subanalysis.
11 r surgery were included in this prespecified
subanalysis.
12 eteen of 790 patients were eligible for this
subanalysis;
358 were treated with ADT plus docetaxel, a
13 ients eligible for the present retrospective
subanalysis,
46 had ER homogeneous MBC and 56 had ER het
14 In this
subanalysis,
acetylcysteine did not reduce the risk of c
15 There were insufficient data to perform a
subanalysis among pediatric secondary cases.
16 To demonstrate feature
subanalysis and error correction of optical coherence to
17 Results of the
subanalysis are sufficient to generate the hypothesis th
18 e controlled for duration of serostatus in a
subanalysis,
as well as comorbidities and other factors
19 A
subanalysis assessed the impact of different zero-shot p
20 Subanalysis at 3 mo post-LT revealed more aCKD events in
21 In a
subanalysis based on 61 patients with apical TTS and 56
22 In
subanalysis,
birth >90 minutes from a CSC was associated
23 Subanalysis by cancer type and chemotherapy suggested th
24 Subanalysis by FEVR stage showed the same microvascular
25 A separate
subanalysis categorized websites into institutional and
26 In a
subanalysis cohort of 1396 women with HIV, increased rep
27 A
subanalysis combining discovery GWAS showed an attenuati
28 sk or very high risk of 14 041 patients in a
subanalysis combining the tuning and internal geographic
29 is a practical technique since each CE-MS/MS
subanalysis consumes <10 nL, and each CE-MS/MS subanalys
30 e marrow fat loss on T1-weighted MRI; in the
subanalysis,
DECT fat map specificity was higher than th
31 Conclusion This
subanalysis demonstrated improved PFS with lenvatinib tr
32 A
subanalysis demonstrated that among patients with a hist
33 A
subanalysis demonstrated that the better fit of the CPI
34 alth insurance and socioeconomic status in a
subanalysis did not significantly alter these results.
35 Subanalysis during 2 study periods (2013 to 2015 and 201
36 No
subanalysis (
e.g. limited to cases as outcome) demonstra
37 For this
subanalysis,
ER expression in the biopsied metastasis wa
38 This
subanalysis evaluates patients with a history of class I
39 Subanalysis evaluating the percentage of eyes achieving
40 This
subanalysis examined the relationship between eplerenone
41 This
subanalysis examines baseline prevalence and in-trial in
42 In a
subanalysis excluding possible and near-SUDEP cases, lon
43 Subanalysis explored those with polycystic kidney diseas
44 ed from December 2021 to March 2022, and the
subanalysis focused on diversion was conducted from Dece
45 Subanalysis for lung lesions (n = 46) was also performed
46 Subanalysis for lung lesions yielded similar results (pr
47 A
subanalysis for patients with a high level of alpha-feto
48 y margin of 0.20 mm), except in the post hoc
subanalysis for the BMS-ISR group (-0.203 mm [95% CI, -0
49 An era effect
subanalysis found that, in studies published after 1994,
50 We did an in-depth
subanalysis from a global dataset of national cancer con
51 This study represents a
subanalysis from the multicenter EuroTR registry (Europe
52 d in all antibiotic classes studied and in a
subanalysis having breast cancer fatality as the outcome
53 We also performed a
subanalysis in 130 adult patients with acute viral myoca
54 ct of treatment on mortality, we performed a
subanalysis in families with at least 1 untreated deceas
55 riables are manipulated during each CE-MS/MS
subanalysis in order to maximize sequence coverage.
56 This
subanalysis included a total of 13 026 participants (mea
57 A post hoc
subanalysis included adults who received a 2-day split-d
58 ertension) did not differ between races, but
subanalysis indicated more African American nondonation
59 In a pre-specified
subanalysis,
information omissions for new ICU patients
60 This prespecified
subanalysis investigated the effect of age on the effica
61 A
subanalysis investigated the effect of MRI parameters on
62 This
subanalysis involved 208 prospectively included patients
63 The
subanalysis is limited by the relatively small number of
64 d to increased risk of AIDS or SNAEs, but in
subanalysis,
LLV 200-999 copies/mL was associated with S
65 Manual quantitative OCT
subanalysis may allow a more precise understanding of an
66 Quantitative
subanalysis may be useful in studying the differential m
67 In a
subanalysis,
monoclonal (M)-protein concentration and ty
68 In a
subanalysis,
normalising for total-tau, none of the nove
69 A
subanalysis of 10 804 participants including adjustment
70 In a
subanalysis of 100 subjects with blood plasma HIV <50 co
71 significant associations were also seen in a
subanalysis of 1092 ACPA-negative patients (HAQ 0.15, 0.
72 Concordance estimates were similar in a
subanalysis of 16 studies from high-TB-burden countries.
73 In a
subanalysis of 18 pairs concordant for PD, the twin with
74 In this prespecified
subanalysis of 183 patients (58.1+/-10.2 years; 33% wome
75 A
subanalysis of 186 case subjects with sporadic IPF confi
76 A
subanalysis of 43 slides evaluated by each CellScope rea
77 In this prespecified
subanalysis of 473 patients (54+/-8 years, 53% men) who
78 A
subanalysis of 62 patients matched for equivalent baseli
79 This was a preplanned
subanalysis of a large randomized controlled trial of ea
80 This study, a
subanalysis of a larger study to understand recruitment
81 DESIGN, SETTING, AND PARTICIPANTS: This is a
subanalysis of a previously reported subgroup of patient
82 A
subanalysis of a prospective randomized trial suggested
83 Materials and Methods This post hoc
subanalysis of a prospective research cohort included pa
84 Subanalysis of a prospective, observational cohort of pa
85 Subanalysis of a randomized study of atorvastatin 80 mg/
86 In this
subanalysis of a randomized trial of patients with polyc
87 This was a predefined
subanalysis of a single-center prospective randomized st
88 Materials and Methods A retrospective
subanalysis of a single-center prospective registry stud
89 On
subanalysis of adults and elderly patients, the prevalen
90 In a
subanalysis of animals matched for the degree of hypergl
91 ; OR 12.0 [1.8-513.0], p=0.0034); and in the
subanalysis of any extrapelvic lesions (none [0%; 0-6] v
92 detection and may be useful for quantitative
subanalysis of clinically relevant features, such as sub
93 A retrospective
subanalysis of combined data from 10 phase II/III double
94 clerosis, a stroke quality initiative, and a
subanalysis of DAPAHF (Study to Evaluate the Effect of D
95 This study is a retrospective
subanalysis of HARBOR (a phase 3, double-masked, multice
96 A further
subanalysis of hemodynamic changes was performed on the
97 In this retrospective
subanalysis of high-risk, symptomatic aortic stenosis pa
98 Subanalysis of influenza B patients showed faster RNA de
99 ctor in the early phase after OLT, as in our
subanalysis of IRI patients, PCT values < 15 mcg/l were
100 A
subanalysis of non-Hispanic African-American and white c
101 ected in this study are modest, quantitative
subanalysis of OCT images may be of greater clinical rel
102 A
subanalysis of only studies at low risk of bias demonstr
103 Subanalysis of paired cases based on pretreatment ultras
104 However, in a
subanalysis of patients older than 60 years, proximal po
105 toxicity and discontinuation were found in a
subanalysis of patients on methotrexate not receiving fo
106 In a
subanalysis of patients with a normal LV ejection fracti
107 This is a
subanalysis of patients with at least 1 TO in the SYNTAX
108 A
subanalysis of patients with blood cultures (n = 7,482)
109 In a
subanalysis of patients with blood cultures drawn (n = 1
110 In the
subanalysis of patients with GCA, the 5-year risk of any
111 days (22.7% vs 23.2%; P = 1.000), even in a
subanalysis of patients with high-risk source of infecti
112 Subanalysis of patients with liver-only recurrence revea
113 However,
subanalysis of patients with locoregional disease (clini
114 A
subanalysis of patients with VKH from the First-line Ant
115 tive value could further be increased in the
subanalysis of patients with whole-liver treatment, wher
116 In a
subanalysis of primary STS, DSS was significantly longer
117 In a
subanalysis of primary STS, DSS was significantly longer
118 Subanalysis of recipient race revealed that in blacks on
119 Subanalysis of recipients with yr1 estimated glomerular
120 The aim of this
subanalysis of RESCUE trial data was to assess the effec
121 In a
subanalysis of studies in which delayed imaging was perf
122 In a
subanalysis of the 900 of 1182 patients (76.1%) in the i
123 G, AND PARTICIPANTS: This was a prespecified
subanalysis of the ARTESiA population who received treat
124 Results of this
subanalysis of the ARTESiA randomized clinical trial fou
125 DESIGN, SETTING, AND PARTICIPANTS: This
subanalysis of the Chronic Rhinosinusitis Epidemiology S
126 Similarly,
subanalysis of the cohort with HbA1c levels drawn 0 to 2
127 Methods and Results In a
subanalysis of the CULPRIT-SHOCK trial (Culprit Lesion O
128 A
subanalysis of the donor arrest group demonstrated simil
129 A recent
subanalysis of the EAST-AFNET 4 (Early Treatment of Atri
130 A
subanalysis of the effect of lung allocation score was a
131 We report on a
subanalysis of the effects of losartan and atenolol on c
132 Results of this
subanalysis of the FIDELITY analysis suggest that CKD-as
133 This study is a
subanalysis of the Multicenter International Study for T
134 This
subanalysis of the multicenter TriValve (Transcatheter T
135 19.2; p=0.0026) at the patient level; in the
subanalysis of the pelvic nodes region (four [8%; 2-19]
136 Thus, the present
subanalysis of the PRECISE-MDT study analyzed patients w
137 This prespecified
subanalysis of the randomized EAST-AFNET4 trial (Early T
138 Design, Setting, and Participants: This
subanalysis of the randomized Prolonging Dual Antiplatel
139 This is a
subanalysis of the SYNTAXES (Synergy Between PCI With Ta
140 The correlation was also present on
subanalysis of the thoracic and upper part of the abdomi
141 This
subanalysis of the TNT (Treating to New Targets) study i
142 Materials and Methods An exploratory
subanalysis of the TOmosynthesis plus SYnthesized MAmmog
143 Materials and Methods This exploratory
subanalysis of the Tomosynthesis plus Synthesized Mammog
144 In this prespecified
subanalysis of the TWILIGHT trial, we evaluated the trea
145 Subanalysis of the United Kingdom Royal College of Ophth
146 We did a
subanalysis of this placebo group to test the hypothesis
147 We did a
subanalysis of this population to compare the screening
148 In a
subanalysis of vitamin D-deficient participants, sun exp
149 This
subanalysis of WIN-R was conducted to evaluate the effic
150 The neuroradiologic
subanalysis on 11 patients with WS exhibited bilateral t
151 cervical, and/or rectal swabs; with separate
subanalysis on GBS bacteriuria).
152 s using a random-effects model and conducted
subanalysis on region.
153 In this
subanalysis,
only patients with complete data on height
154 Subanalysis performed combining grade and flow showed th
155 In the
subanalysis,
responders lived longer than patients with
156 However, in a
subanalysis restricted to 2014-2018, differences in graf
157 In the
subanalysis restricted to APOE3/3 and APOE3/4 genotypes,
158 raction remained significant in a predefined
subanalysis restricted to APOE3/3 and APOE3/4 genotypes.
159 In a
subanalysis restricted to gender-comparable sports, boys
160 Subanalysis revealed differences between prompts on text
161 Subanalysis revealed that the greatest visual gains at 5
162 In the
subanalysis,
seasonal variation was found in acute appen
163 Subanalysis showed an OR of 9.29 (CI, 3.94 to 21.91) for
164 ence in secondary outcomes, but per-protocol
subanalysis showed fewer hospital assessments when careg
165 Subanalysis showed no difference in accuracy pre- versus
166 Subanalysis showed that the NCCP group could be divided
167 Subanalysis showed that this was primarily among patient
168 utaneous Coronary Intervention) (n = 11,154)
subanalysis showed, in individuals with type 2 diabetes
169 In a
subanalysis stratified by baseline HIV viral load, parti
170 In a
subanalysis,
survival times of responders were compared
171 banalysis consumes <10 nL, and each CE-MS/MS
subanalysis takes approximately 10 min; therefore, sever
172 A
subanalysis that compared opioids users with nonusers sh
173 In a
subanalysis,
the -219G>T GT promoter genotype, associate
174 In a
subanalysis,
the DECT BME map, DECT fat map and DECT ero
175 Under this condition, in each
subanalysis,
the number of peptides available for MS/MS
176 To be eligible for the en face OCT
subanalysis,
the preserved EZ area was required to be li
177 In the
subanalysis,
there was no change in the incident-rate of
178 nual measurement (P < .004); at intrapatient
subanalysis,
this difference was related to the level of
179 was yearly metformin use for >=5 years, with
subanalysis up to 10 years.
180 ated dd-cfDNA was defined as >=0.12%, with a
subanalysis using a threshold of 0.20%.
181 In a
subanalysis using data from the 1958 cohort only, geneti
182 The top association from the
subanalysis was at rs1902491 (P value 2.81 x 10(-5)), a
183 A separate
subanalysis was carried out for families with a history
184 A
subanalysis was completed for children treated with 0.55
185 A
subanalysis was completed to determine whether risk fact
186 A retinopathy-only
subanalysis was conducted in 437 subjects by removing th
187 Subanalysis was performed by symptom status at the time
188 A
subanalysis was performed comparing the distinct impact
189 This prespecified
subanalysis was performed in 4880 patients enrolled at r
190 As a control, a
subanalysis was performed throughout the same time perio
191 A
subanalysis was performed to assess the association betw
192 The aim of this
subanalysis was to evaluate the incidence and risk facto
193 The purpose of this
subanalysis was to qualitatively describe electrophysiol
194 In a prespecified
subanalysis,
we found that participants in the intervent
195 In the
subanalysis,
we identified 40 DP donors and 22 TA-NRP do
196 safety outcomes of both the trials and this
subanalysis were symptomatic recurrent venous thromboemb
197 sample was systematically increased in each
subanalysis (
while utilizing dynamic exclusion) so that
198 In the
subanalysis with persistent mild GBS in the first 2 week
199 tients were eligible for a direct IGB and RB
subanalysis,
with IGB detecting 15 additional cases.
200 approximately 100 m/z) during each CE-MS/MS
subanalysis without using dynamic exclusion.
201 Subanalysis yielded a specificity of 98.9% (95% CI, 98.3